Polypharmacy and Major Adverse Events in Atrial Fibrillation. Issue 6 (December 2022)

• Record Type: Journal Article
• Authors: Caturano, Alfredo; Spiezia, Serenella; Brunelli, Vincenzo; Galiero, Raffaele; Sasso, Ferdinando Carlo
• Is Part Of: Journal of cardiovascular pharmacology. Volume 80:Issue 6(2022)
• Page Start: 781
• Page End: 782
• Publication Date: 2022-12
• Subjects: polypharmacy -- adverse event -- atrial fibrillation -- frailty -- holistic medicine; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000001363
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract: Atrial fibrillation is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. Polypharmacotherapy is crucial in atrial fibrillation management, and in many of the concomitant comorbidities, such as hypertension, heart failure, coronary artery disease, and diabetes. However, polypharmacy represents a major concern because of the associated risks of adverse events onset, with an increased risk of all-cause mortality and cardiovascular mortality. In this study, we commented data reported by Tsagkaris et al comparing them with previous reports.